HighTower Advisors
BLUE

HighTower Advisors’s bluebird bio BLUE Stock Holding History

HighTower Advisors’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-586
Closed -$6K – 3834
2024
Q3 		$6K Hold
586
– – ﹤0.01% 3582
2024
Q2 		$11K Hold
586
– – ﹤0.01% 3439
2024
Q1 		$15K Hold
586
– – ﹤0.01% 3374
2023
Q4 		$15K Buy
+586
New +$35.7K ﹤0.01% 3414
2018
Q4 		– Sell
-135
Closed -$256K – 2216
2018
Q3 		$256K Buy
135
+22
+19% +$45.4K ﹤0.01% 1811
2018
Q2 		$229K Hold
113
– – ﹤0.01% 1829
2018
Q1 		$250K Buy
113
+14
+14% +$35.6K ﹤0.01% 1761
2017
Q4 		$229K Sell
99
-13
-12% -$26.4K ﹤0.01% 1841
2017
Q3 		$199K Buy
+112
New +$156K ﹤0.01% 1916

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

HighTower Advisors's BLUE Position: Q4 2024 in Review

HighTower Advisors sold out of bluebird bio (BLUE) in Q4 2024, closing a stake of 586 shares — an estimated $6K sold.

HighTower Advisors first reported a position in BLUE in Q3 2017 and held it in 9 quarters. The position peaked at $256K in Q3 2018. 83 funds tracked by Wall St. Rank hold BLUE as of Q4 2024.

  • HighTower Advisors reported no remaining bluebird bio position as of Q4 2024 after selling out during the quarter.
  • HighTower Advisors sold 586 bluebird bio shares in Q4 2024, an estimated $6K.
  • HighTower Advisors first reported a position in bluebird bio in Q3 2017 and held it in 9 quarters.
  • HighTower Advisors's bluebird bio position peaked at $256K in Q3 2018.
  • 83 funds tracked by Wall St. Rank held bluebird bio as of Q4 2024.

Based on HighTower Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.